You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,109,020

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,109,020

Title:	Use of ADCC-optimized antibodies for treating weak patients
Abstract:	The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
Inventor(s):	Bourel; Dominique (La Madeleine, FR), Jorieux; Sylvie (Villeneuve D\'Ascq, FR), Romeuf; Christophe De (Lambersart, FR), Klein; Philippe (Lille, FR), Gaucher; Christine (Sequedin, FR), Bihoreau; Nicolas (Orsay, FR), Nony; Emmanuel (Antony, FR)
Assignee:	LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (Les Ulis, FR)
Application Number:	13/930,070
Patent Claims:	1. A method for treating haemolytic disease of the Previously Presentedborn, Sezary Syndrome, chronic myeloid leukaemias, chronic lymphoid leukaemias (CLL-B), cancer, breast cancer, conditions related to the environment, infectious diseases, chronic fatigue syndrome (CFS), parasitic infections, or viral infections, comprising: administering a composition of antibodies specific to the condition to be treated to a patient homozygous for phenylalanine in position 158 of CD16 (FCGR3A-158F homozygotes) or a patient heterozygous for valine/pheynylalanine in position 158 of CD16 (FCGR3A-158V/F), wherein said antibodies have a biantenary-type Fc domain glycosylation, and wherein the concentration for the forms G0F+G1F is lower than 30%. 2. The method according to claim 1, wherein the dose of said antibody composition administered to the patient is between 2 and 100 times lower than a dose of an antibody composition of the same specificity but of different glycosylation or produced in a CHO line. 3. The method according to claim 2, wherein the dose of said antibody composition administered to the patient is between 5 and 25 times lower than a dose of an antibody composition of the same specificity but of different glycosylation or produced in a CHO line. 4. The method according to claim 1, wherein the antibodies are directed against a non-ubiquitous antigen present in healthy donor cells or an antigen of a pathological cell or of an organism pathogenic for humans. 5. The method according to claim 1, wherein the antibodies are anti-HLA-DR. 6. The method according to claim 1, wherein the antibodies are anti-CD20. 7. The method according to claim 1, wherein said method is for treating a cancer or an infection by a pathogenic agent. 8. The method according to claim 1, wherein the antibodies are selected from the group consisting of anti-HLA-DR, anti-CD20, anti Ep-CAM, anti HER2, anti CD52, anti HER1, anti GD3, anti CA125, anti GD, anti GD2, anti CD-23 and anti Protein C, anti-KIR3DL2, anti-EGFR, anti-CD25, anti-CD38, anti-CD30, anti-CD33, and anti-CD44 and anti-viral antibodies. 9. The method according to claim 1, wherein said method is for treating a cancer of positive HLA class-II cells, B-cell lymphomas, acute B-cell leukaemias, Burkitt's syndrome, Hodgkin's lymphoma, myeloid leukaemias, chronic B-cell lymphoid leukaemias (CLL-B), non-Hodgkin's T-cell leukaemias and lymphomas and chronic myeloid leukaemias. 10. The method according to claim 1, wherein the condition and the antibody composition are selected from: colorectal cancer and anti Ep-CAM antibody composition; B cell lymphoma thrombocytopenia purpura and anti-CD20 antibody composition; ovarian cancer and anti-HER2 antibody composition; RSV and palivizumab antibody composition; leukaemia and anti-CD52 antibody composition; NHL and anti-CD20 antibody composition; cancer and anti-HER1 antibody composition; lung, colorectal, and kidney cancers and anti VEGF antibody composition; non-Hodgkin's lymphoma and anti-CD22 antibody composition; breast, ovarian, prostate cancers and bispecific HER2Neu/CD64 antibody composition; small cell lung carcinoma and anti-GD3 antibody composition; ovarian cancer and anti-CA125 antibody composition; malignant melanoma and anti-GD antibody composition; cancers and EGF antibody composition; cancers and anti-GD2 antibody composition; and prostate cancer and anti-PSMA composition.

Details for Patent 9,109,020

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998	⤷ Try a Trial	2023-07-31
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004	⤷ Try a Trial	2023-07-31
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.